Company intelligence / Profile preview

Arena Neuroscience

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Arena Neuroscience was a wholly owned neuroscience-focused subsidiary of Arena Pharmaceuticals built around Arena’s GPCR small-molecule platform, with its lead clinical-stage program LP352 for treatment‑resistant developmental and epileptic encephalopathies and preclinical programs LP143 and LP659 for microglial neuroinflammatory diseases, before being relaunched as independent company Longboard Pharmaceuticals in 2020.[2][3]

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Arena Pharmaceuticals (founder and equity/royalty participant in the spin-out Longboard Pharmaceuticals)[2][3]

Beyond the preview

Go deeper on Arena Neuroscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arena Neuroscience.

Explore the full profile